2004
DOI: 10.1097/01.inf.0000109221.50972.53
|View full text |Cite
|
Sign up to set email alerts
|

Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants

Abstract: PncDT11 is safe and immunogenic in infants. The use of 11-valent pneumococcal vaccine would increase the serotype coverage beyond the currently available 7-valent vaccine.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
18
0
5

Year Published

2004
2004
2012
2012

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 48 publications
(24 citation statements)
references
References 28 publications
1
18
0
5
Order By: Relevance
“…In addition to PCV7, pneumococcal conjugate vaccines have recently been formulated that contain 9 (7, 19), 11 (8), or 13 serotypes. These new-generation vaccines contain antigen to serotype 5 and are in various stages of clinical trials.…”
Section: Discussionmentioning
confidence: 99%
“…In addition to PCV7, pneumococcal conjugate vaccines have recently been formulated that contain 9 (7, 19), 11 (8), or 13 serotypes. These new-generation vaccines contain antigen to serotype 5 and are in various stages of clinical trials.…”
Section: Discussionmentioning
confidence: 99%
“…La vigilancia de la prevalencia y dispersión de este clon en el país y en otros países de Latinoamérica y del mundo (3-6) resulta útil para evaluar la presión selectiva que pueda generarse por la introducción de las vacunas conjugadas que incluyan el serotipo 5 (7,8). Por tal razón, el objetivo de este estudio fue establecer, por medio de la determinación de los patrones de restricción de PFGE, las relaciones genéticas entre los aislamientos invasores de S. pneumoniae serotipo 5 recuperados entre 1994 y 2004 y el clon 19-Colombia 5 , con el fin de actualizar la información y contribuir con el programa de vigilancia molecular del neumococo.…”
unclassified
“…Current vaccines comprise epidemiologically dominant serotype-based selections of pneumococcal capsular polysaccharides, conjugated or not to a carrier protein (Dagan et al, 2004;Fedson & Musher, 2004;Mbelle et al, 1999;Smart et al, 1987). However, the vaccine formulations do not cover all serotypes of S. pneumoniae, which might be of particular relevance in certain regions that have different dominant serotypes (Dagan et al, 1992).…”
Section: Introductionmentioning
confidence: 99%